Polymerase Chain Reaction Market – Insights
Polymerase chain reaction (PCR) is extensively used for DNA amplification technique. It generates thousands to millions of copies of a particular DNA sequence. The PCR industry is shifting its focus away from macro-scale systems and is focused on developing the micro-scale devices. Micro-scale devices offer various benefits such as micro-scale sample sizes requires less blood from patients, it takes less reaction time and also offers cost-effective benefits, as many microfluidic devices are manufactured from inexpensive polymers. Increasing adoption of polymerase chain reaction in various diagnostic and research application, growing research and development funding in gene therapy, and continuous technological advancement in polymerase chain reaction are projected to augment growth of the market over the forecast period.
The global polymerase chain reaction market was valued at US$ 3.7 billion in 2017 and is expected to witness a CAGR of 8.8% over the forecast period (2017 – 2025).
Global Polymerase Chain Reaction Market Share (%), By Product Type
Source: Coherent Market Insights Analysis (2018)
Increasing Numbers of Product Launches and Collaborations in Polymerase Chain Reaction are expected to Drive Growth of the Polymerase Chain Reaction Market
Key players in the polymerase chain reaction market are engaged in launching advanced and novel PCR instruments and consumables, which will allows rapid and easy nucleic acid amplification. For instance, in October 2017, Diatech Pharmacogenetics srl launched easyPGX: a ready to use in-vitro diagnostic real-time PCR product line and Helix: a polymerase chain reaction kit for the extraction of circulating free DNA from plasma. In September 2015, Bio-Rad Laboratories launched droplet digital PCR (ddPCR) Supermix for Residual DNA Quantification. The new supermix designed to use with Bio-Rad’s Droplet Digital PCR Systems offers highly precise and sensitive method for DNA measurement. In November 2014, Chai Biotechnologies Inc. introduced Open qPCR: Real-Time PCR Thermocycler. The new instrument is designed to use for genetic genotyping, pathogen detection, and relative DNA quantification. Moreover, in April 2014, Bio-Rad Laboratories launched Precision Blue Real-Time PCR Dye. The new Precision Blue dye is compatible with Bio-Rad’s universal qPCR supermixes, and can be used with all Bio-Rad’s CFx real time PCR systems.
Furthermore, key players are involved in several collaborations to expand their geographical horizon and increase patient reach. For instance, in March 2018, Akonni Biosystems Inc. and a Chinese in-vitro diagnostics company: Righton signed a commercial agreement, which enables Righton to sell Akonni's TruDiagnosis and TruTip Nucleic Acid Purification Kits in China. TruDiagnosis is based on proprietary on-slide PCR and gel-drop microarray technology. In January 2018, Thermo Fisher Scientific and Illumina, Inc. signed a commercial agreement. Under the agreement, Thermo Fisher will provide Ion AmpliSeq technology to Illumina for research purpose. Moreover, in December 2017, Genome Diagnostics (GenDx) signed a global reseller agreement with Thermo Fisher Scientific, assigning GenDx as a non-exclusive reseller of Thermo Fisher’s QuantStudio real-time PCR instrument. Under the agreement, GenDx will market the QuantStudio real-time PCR in the Netherlands and other European countries. Thus, significant organic and inorganic growth strategies by various key players is driving growth of the polymerase chain reaction market.
Increasing Prevalence of Chronic and Infectious Disease are Driving Growth of Polymerase Chain Reaction Market
Polymerase chain reaction is increasingly used in clinical diagnosis of infectious disease, nucleic acid amplification, paternity testing, DNA fingerprinting, detection and diagnosis of infectious disease, quality control, and personalized medicine. For instance, according to the Centers for Disease Control and Prevention (CDC), around 5,251 deaths due to the influenza infection were registered in 2015, in U.S. According to the World Health Organization (WHO), in 2015, around 32,000 estimated deaths were reported from tuberculosis and around 3, 23,000 new cases of TB cases were registered in the European region. According to the National Ambulatory Medical Care Survey: 2015 data findings, 16.8 million visits to physician offices for infectious and parasitic diseases were registered in the U.S. According to the World Health Organization (WHO), 2016, around 555,318 new cases of cancer were reported in 2012, in the Middle East Region. The region is expected to witness the highest relative increase of cancer cases among the regions in the world accounting to 961,098 cases by 2030. Moreover, according to the Cancer Atlas, 2012, about 1.1 million new cancer cases and 600,000 cancer deaths occurred annually in Latin America and the Caribbean, where lung cancer is the leading cause of cancer death for both genders combined in the region.
However, advances in research are leading to generation of various alternative nucleic acid amplification methods, which may hinder growth of the polymerase chain reaction market over the forecasted period. Such alternative methods of nucleic acid amplification includes loop medicated isothermal amplification, nucleic acid sequence based amplification, strand displacement amplification, and multiple displacement amplification. These methods offers better applicability and sensitivity in nucleic acid amplification, where PCR shows limitations such as contamination, sensitivity to certain classes of contaminants and inhibitors, and requirement of thermal cycling. Key players in the polymerase chain reaction are engaged in offering PCR-free nucleic acid detection methods. For instance, in March 2018, Quanterix Corporation and DestiNA Genomics collaborated to develop PCR-free microRNA detection method with high-specificity and ultra-sensitivity, thereby enhancing RNA biomarker detection.
Key players operating in polymerase chain reaction market include F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., bioMérieux, S.A., Enzo Life Science, Inc., Abbott Laboratories, Takara Bio Inc., Becton, Dickinson and Company, and Danaher Corporation.